BLBin Liu

Bin Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bin Liu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Bo Jia

    Department of Urology China‐Japan Union Hospital of Jilin University Changchun Jilin 130033 China

    1 shared publication
  • Kelong Fan

    CAS Engineering Laboratory for Nanozyme Key Laboratory of Biomacromolecules (CAS) CAS Center for Excellence in Biomacromolecules Institute of Biophysics Chinese Academy of Sciences Beijing 100101 China

    1 shared publication
  • Lei Ji

    Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.

    1 shared publication
  • Qingling Zhang

    Department of Dermatology China‐Japan Union Hospital of Jilin University Changchun Jilin 130033 China

    1 shared publication
  • Wei Jiang

    Academy of Medical Sciences, Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou, Henan, China

    1 shared publication
  • Xinlu Yu

    Department of Otolaryngology Second Hospital of Jilin University Changchun Jilin 130041 China

    1 shared publication

Latest Publications

  • Open Access

    NIR‐Activatable Domino Cascade Catalysis Nanozyme Reactor for Multi‐Mechanism Synergistic Immunotherapy in Bladder Cancer

    by Yongnan Jiang, Qingling Zhang, Yuhan Zhang, Xinlu Yu, Bo Jia, Yulong Dong, Yalong Wu, Kelong Fan, Xinquan Gu, Lei Ji, et al.

    Current intravesical therapies for bladder cancer after resection are limited by poor tissue penetration, off‐target effects, and insufficient efficacy. To address these challenges, this study designs a thermo‐responsive hydrogel (PNH) that encapsulates chitosan (CS)‐coated Fe/Mn bimetallic nanozymes (FMCC) together with cholesterol oxidase (ChOx). FMCC displays multiple enzyme‐mimicking activities, including peroxidase (POD), catalase (CAT), and glutathione oxidase (GSHox). ChOx amplifies this catalytic cascade, enhancing reactive oxygen species (ROS) production and inducing ferroptosis‐mediated tumor cell death. The CS coating improves mucosal adhesion and tissue permeability, thereby facilitating intravesical delivery. Upon near‐infrared (NIR) irradiation, FMCC generates heat that liquefies the hydrogel, enabling spatiotemporally controlled drug release and providing mild photothermal therapy (MPTT). This photothermal effect acts synergistically with ferroptosis induction and immune modulation, concurrently minimizing damage to normal tissues. In parallel, ChOx disrupts cholesterol‐rich membrane rafts and promotes pro‐inflammatory M1 macrophage polarization. Released Mn 2+ ions further potentiate immune activation by stimulating the cGAS–STING pathway, driving IFN‐β and IL‐6 secretion, dendritic cell maturation, and T cell infiltration. Together, this nanozyme–hydrogel system integrates tissue penetration, metabolic disruption, and immune stimulation, representing a promising strategy for localized bladder cancer therapy.